Amicus Therapeutics (FOLD) Expected to Announce Earnings on Thursday

Key Points

• Amicus will report Q1 2026 results before the market opens on Thursday, May 7, 2026 at 8:30 AM ET; analysts expect EPS $0.0375 and revenue $162.506 million.
• In the prior quarter the company missed EPS ($0.10 vs. $0.13) while revenue rose 23.7% year‑over‑year; analysts project $0 EPS for the current fiscal year and $1 for next year, and the consensus rating is a Hold with an average price target of $15.39.
• Shares trade around $14.49 with a market cap of $4.55 billion (1‑year high $14.50), the CEO sold 22,500 shares in March, and institutions such as Goldman Sachs and UBS recently increased their stakes.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) is anticipated to release its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Amicus Therapeutics to post earnings of $0.0375 per share and revenue of $162.5060 million for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:30 AM ET.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last issued its earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, missing analysts' consensus estimates of $0.13 by ($0.03). The business had revenue of $185.21 million for the quarter, compared to analyst estimates of $185.00 million. Amicus Therapeutics had a positive return on equity of 4.15% and a negative net margin of 4.27%.The firm's revenue for the quarter was up 23.7% on a year-over-year basis. During the same period last year, the company posted $0.09 earnings per share. On average, analysts expect Amicus Therapeutics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD opened at $14.49 on Thursday. The stock has a market capitalization of $4.55 billion, a price-to-earnings ratio of -181.13 and a beta of 0.48. Amicus Therapeutics has a 1-year low of $5.51 and a 1-year high of $14.50. The company's fifty day moving average is $14.41 and its two-hundred day moving average is $12.65. The company has a debt-to-equity ratio of 1.43, a quick ratio of 1.88 and a current ratio of 2.84.

Insider Buying and Selling at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 22,500 shares of the firm's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $14.35, for a total transaction of $322,875.00. Following the completion of the transaction, the chief executive officer owned 998,680 shares in the company, valued at approximately $14,331,058. This trade represents a 2.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 2.20% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in FOLD. Goldman Sachs Group Inc. grew its position in Amicus Therapeutics by 7.7% in the first quarter. Goldman Sachs Group Inc. now owns 2,703,577 shares of the biopharmaceutical company's stock worth $22,061,000 after buying an additional 194,213 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in Amicus Therapeutics by 11.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,072,474 shares of the biopharmaceutical company's stock worth $8,751,000 after buying an additional 113,803 shares during the last quarter. Intech Investment Management LLC grew its position in Amicus Therapeutics by 37.1% in the first quarter. Intech Investment Management LLC now owns 170,922 shares of the biopharmaceutical company's stock worth $1,395,000 after buying an additional 46,218 shares during the last quarter. Strs Ohio acquired a new position in Amicus Therapeutics in the first quarter worth approximately $30,000. Finally, Cetera Investment Advisers acquired a new position in Amicus Therapeutics in the second quarter worth approximately $79,000.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on FOLD. Zacks Research cut shares of Amicus Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Monday, January 26th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Amicus Therapeutics in a research report on Friday, March 27th. Jefferies Financial Group reiterated a "hold" rating and issued a $14.50 target price (down from $16.00) on shares of Amicus Therapeutics in a research report on Thursday, January 22nd. Finally, Guggenheim lowered shares of Amicus Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, January 5th. Three investment analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and an average price target of $15.39.

About Amicus Therapeutics

Amicus Therapeutics NASDAQ: FOLD is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company's lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.